Myriad Genetics Statistics
Total Valuation
MYGN has a market cap or net worth of $1.56 billion. The enterprise value is $1.68 billion.
Important Dates
The next confirmed earnings date is Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MYGN has 90.82 million shares outstanding. The number of shares has increased by 7.39% in one year.
| Shares Outstanding | 90.82M |
| Shares Change (YoY) | +7.39% |
| Shares Change (QoQ) | +0.78% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 96.58% |
| Float | 83.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 115.51 |
| PS Ratio | 1.96 |
| Forward PS | 1.86 |
| PB Ratio | 2.21 |
| P/FCF Ratio | n/a |
| PEG Ratio | 2.15 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.96 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.28 |
Financial Efficiency
Return on equity (ROE) is -21.03% and return on invested capital (ROIC) is -7.08%.
| Return on Equity (ROE) | -21.03% |
| Return on Assets (ROA) | -5.68% |
| Return on Capital (ROIC) | -7.08% |
| Revenue Per Employee | $297,111 |
| Profits Per Employee | -$57,481 |
| Employee Count | 2,700 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 10.21 |
Taxes
| Income Tax | -1.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.59% in the last 52 weeks. The beta is 1.94, so MYGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.94 |
| 52-Week Price Change | +1.59% |
| 50-Day Moving Average | 25.35 |
| 200-Day Moving Average | 23.82 |
| Relative Strength Index (RSI) | 20.81 |
| Average Volume (20 Days) | 708,904 |
Short Selling Information
The latest short interest is 4.49 million, so 4.95% of the outstanding shares have been sold short.
| Short Interest | 4.49M |
| Short Previous Month | 4.19M |
| Short % of Shares Out | 4.95% |
| Short % of Float | 5.40% |
| Short Ratio (days to cover) | 6.48 |
Income Statement
In the last 12 months, MYGN had revenue of $802.20 million and -$155.20 million in losses. Loss per share was -$1.78.
| Revenue | 802.20M |
| Gross Profit | 554.10M |
| Operating Income | -103.30M |
| Pretax Income | -156.60M |
| Net Income | -155.20M |
| EBITDA | -49.00M |
| EBIT | -103.30M |
| Loss Per Share | -$1.78 |
Full Income StatementBalance Sheet
The company has $97.30 million in cash and $143.30 million in debt, giving a net cash position of -$46.00 million or -$0.51 per share.
| Cash & Cash Equivalents | 97.30M |
| Total Debt | 143.30M |
| Net Cash | -46.00M |
| Net Cash Per Share | -$0.51 |
| Equity (Book Value) | 740.50M |
| Book Value Per Share | 8.15 |
| Working Capital | 142.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$92.80 million and capital expenditures -$32.80 million, giving a free cash flow of -$125.60 million.
| Operating Cash Flow | -92.80M |
| Capital Expenditures | -32.80M |
| Free Cash Flow | -125.60M |
| FCF Per Share | -$1.38 |
Full Cash Flow StatementMargins
Gross margin is 69.07%, with operating and profit margins of -12.88% and -19.35%.
| Gross Margin | 69.07% |
| Operating Margin | -12.88% |
| Pretax Margin | -19.52% |
| Profit Margin | -19.35% |
| EBITDA Margin | -6.11% |
| EBIT Margin | -12.88% |
| FCF Margin | -17.61% |
Dividends & Yields
MYGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.39% |
| Shareholder Yield | -7.39% |
| Earnings Yield | -9.50% |
| FCF Yield | -7.69% |
Dividend DetailsAnalyst Forecast
The average price target for MYGN is $28.18, which is 63.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.18 |
| Price Target Difference | 63.74% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 7.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
MYGN has an Altman Z-Score of 2.71 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.71 |
| Piotroski F-Score | 4 |